S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Watch for your Federal QR code (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Watch for your Federal QR code (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Watch for your Federal QR code (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Watch for your Federal QR code (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Watch for your Federal QR code (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Watch for your Federal QR code (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Watch for your Federal QR code (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Watch for your Federal QR code (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Watch for your Federal QR code (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Watch for your Federal QR code (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
Corruption scandals cast a shadow over Portugal’s early general election and may favor populists
Watch for your Federal QR code (Ad)
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
Watch for your Federal QR code (Ad)
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high

Rite Aid Stock is Getting Cheap Enough to Buy Here

Rite Aid Stock is Getting Cheap Enough to Buy Here Drugstore operator Rite Aid Corporation NYSE: RAD stock has been pummeled since hitting a post-pandemic high of $32.48 on Jan. 28, 2021. The Company was a benefactor from the pandemic as traffic increased from COVID testing and vaccination distribution. However, as the populace recovers and pandemic traffic falls, its core business is showing a reversion back to… sucky (for lack of a better word). Rite Aid hit a sentiment low point on April 7, 2022, when Deutsche Bank downgraded it to a Sell rating with a rock bottom price target of $1 on the post-pandemic recessive effects as a going concern. As the pandemic migrates to the rearview mirror, so do any prospects of profits for Rite Aid. It’s fiscal Q4 2022 earnings surprised investors by nearly doubling the loss estimates by analysts. The Company lost (-$1.63) per-share in fiscal Q4 2022 after hitting a profit of $0.38 in fiscal Q1 2021. Doom and gloom is the sentiment for Rite Aid shares, but there could be an opportunity for value players especially with a short interest that’s north of 30%. It’s still one of the largest pharmacy benefits managers (PBM) in the country generating over $23 billion in annual sales. Its assets could be a benefit to a larger player. Note that Walgreens NYSE: WBA purchased 1,932 stores and three distribution centers for $4.375 billion in March 2018 after initial attempts to acquire the whole Company at $9 per share was blocked by regulators in 2015. Risk-tolerant investors looking for a value and potential acquisition play can look for opportunistic pullbacks in shares of Rite Aid.

Q4 Fiscal 2022 Earnings Release


On April 14, 2021, Rite Aid released its fiscal fourth-quarter 2022 results for the quarter ending February 2022. The Company reported an earnings-per-share (EPS) loss of (-$1.63) excluding non-recurring items versus consensus analyst estimates for a loss of (-$0.57), a $1.06 miss. Revenues grew 2.5% year-over-year (YoY) to $6.07 billion, beating analyst estimates for $5.96 billion. Rite Aid CEO, Heyward Donigan commented, ““We exceeded our 2022 plan amid continuing challenges of the COVID-19 pandemic. As we look forward to the year ahead, we are ready and energized to compete in a new post-pandemic normal. We demonstrated the important role that pharmacists play in the everyday health of our customers and are well-positioned to grow in a trillion-dollar pharmacy market through our continued leadership as a full-service pharmacy company.”

Improved Full-Year Fiscal 2023 Guidance 

Rite Aid issued fiscal full-year 2023 EPS between (-$1.06) to (-$0.53) versus (-$1.22) consensus analyst estimates. The Company expects revenues of $23.1 billion to $23.5 billion versus $23.44 billion analyst estimates. Fiscal 2023 adjusted EBITDA is expected between $460 million to $500 million and expects savings of $170 million on its cost rationalization program.

Conference Call Takeaways

CEO Donigan maintained a positive and optimistic tone, “I'm really excited to talk to you today about our strategy for fiscal '23 and beyond. But before I outline our growth plan for fiscal '23, I'd like to talk briefly about our expectations for our business as we move beyond the height of the pandemic… It's important to note that COVID's impact on our business was not solely a tailwind. While we saw benefits from the pandemic-related services we provided, COVID also brought significant headwinds to our business. Those included supply chain pressures impacting our inventory and sales, store traffic shifting due to continued work from home, which especially impacts urban areas, and a tightening labor market.” He tried to pacify concerns about the business in the post-Covid era and a return to an improved normal. As consumers reduce their mask-wearing, the Company is seeing a boost in prescriptions and OTC products for cold, flu and cough especially for supers spreaders, kids. Maintenance prescriptions and ancillary vaccines are seeing an increase in demand since they couldn’t get them when receiving COVID vaccines. He is seeing the drop COVID vaccine business being partially mitigated by other important vaccines as well as seeing an uptick in COVID antivirals like Paxlovid. Rite Aid administer 14.3 million COVID vaccines and 3.6 million PCRF tests in fiscal full-year 2022. He flipped the narrative, “In summary, passing the peak of COVID represents a positive inflection point for our business. And we are excited to leverage what we learned, continue to be really nimble and take advantage of the growth opportunities available to us.” CEO Donigan stressed the growth driver moving forward is the pharmacy business with a $1 trillion TAM. He elaborated on plans of expanding their PBM footprint in underserved areas and bolstering its tools to help pharmacists provide value-added services. He expects EBITDA growth of 10% to 20% by fiscal 2025 from fiscal 2022 levels.  

RAD Opportunistic Pullback Levels

Using the rifle charts on the weekly and daily time frames enables a precise view of the playing field for RAD stock. The weekly rifle chart breakdown formed on the nasty earnings reaction as share collapsed for the past two-weeks. The Deutsche Bank analyst downgrade to $1 caused a stampede of selling ahead of its disastrous fiscal Q4 2022 earnings release enabling it to put in a bottom ahead of time. The weekly 5-period moving average (MA) support is falling at $19.11 with 15-period MA at $18.90. The weekly lower Bollinger Bands (BBs) overlap the $13.71Fibonacci (fib) level. The weekly market structure high (MSH) sell triggered under $22.96. The weekly stochastic crossed down off the 30-band as a weekly inverse pup breakdown starts to form. The daily rifle chart downtrend has the 5-period MA at $16.08 with the oversold daily stochastic attempting to coil off the 5-band. The daily market structure low (MSL) triggers above $16.34. The daily 15-period is nearing the $18.61 fib. Prudent investors can monitor for opportunistic pullback levels at the $15.18 fib, $14.53 fib, $13.71 fib, $12.24 fib, and the $10.52 fib. Upside trajectories range from the $18.61 fib up towards the $25.81 fib.

Rite Aid Stock is Getting Cheap Enough to Buy Here

      

→ Laser breakthrough could send stock soaring 2,467% (From Behind the Markets) (Ad)

Should you invest $1,000 in Rite Aid right now?

Before you consider Rite Aid, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rite Aid wasn't on the list.

While Rite Aid currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Rite Aid (RAD)
0.2722 of 5 stars
$0.00-100.0%N/A-0.04$1.00
Compare These Stocks  Add These Stocks to My Watchlist 

Jea Yu

About Jea Yu

  • JeaYu21@gmail.com

Contributing Author

Trading Strategies

Experience

Jea Yu has been a contributing writer for MarketBeat since 2018.

Areas of Expertise

Equities, options, ETFs and futures; fundamental, qualitative, quantitative and technical analysis and pattern identification; active and swing trading; trading systems and methodology development

Education

Bachelor of Arts, University of Maryland, College Park

Past Experience

U.S. equity markets trader, writer and analyst for over 25 years. Published four books by publishers McGraw-Hill, John Wiley & Sons, Marketplace Books and Bloomberg Press. Speaker at various expos and seminars and has been quoted and featured in USA Today, The Wall Street Journal, Traders Magazine, The Financial Times and various trade publications, including Stocks & Commodities, Active Trader and Online Investor.


Featured Articles and Offers

Search Headlines: